Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD

Respiratory Research

Bartolome R Celli⁵  Felipe Cortopassi²  Miguel Divo⁵  Rebeca Baz³  Hildegarde Paz²  Salah Zeineldine²  Elizabeth Cordoba³  Nerea Varo¹  Henneth Corado²  Juan P de Torres¹  Hana Müllerova⁴  Ciro Casanova³  Victor Pinto-Plata⁶ 

[1] Clinica Universidad de Navarra, Pamplona, Spain;Pulmonary-Critical Care Medicine Division, St Elizabeth’s Medical Center, Boston, MA, USA;Hospital Universitario Ntra Sra de Candelaria, Tenerife, Spain;Epidemiology Department, GlaxoSmithKline R&D, Uxbridge, Middlesex, UK;Pulmonary-Critical Medicine Division Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;Pulmonary and Critical Care Medicine Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA, 02115, USA

关键词: Survival;    Repair;    Phenotypes;    Inflammation;    Exercise;   

Others  :  796681
DOI  :  10.1186/1465-9921-13-71

 received in 2012-01-25, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

Background

The relationship between serum biomarkers and clinical expressions of COPD is limited. We planned to further describe this association using markers of inflammation and injury and repair.

Methods

We studied lung function, comorbidities, exercise tolerance, BODE index, and quality of life in 253 COPD patients and recorded mortality over three years. Serum levels of Interleukins 6,8 and16, tumor necrosis factor alpha (TNF α) [inflammatory panel], vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP-9) [injury and repair panel] and pulmonary and activation-regulated chemokine (PARC/CCL-18) and monocyte chemotactic protein 1 (MCP-1/CCL2) [chemoattractant panel] were measured. We related the pattern of the biomarker levels to minimal clinically important differences (MCID) using a novel visualization method [ObServed Clinical Association Results (OSCAR) plot].

Results

Levels of the inflammatory markers IL-6, TNF α were higher and those of injury and repair lower (p < 0.01) with more advanced disease (GOLD 1 vs. 4). Using the OSCAR plot, we found that patients in the highest quartile of inflammatory and lowest quartile of injury and repair biomarkers level were more clinically compromised and had higher mortality (p < 0.05).

Conclusions

In COPD, serum biomarkers of inflammation and repair are distinctly associated with important clinical parameters and survival.

【 授权许可】

   
2012 Pinto-Plata et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR: The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004, 23(1):28-33.
• [2]Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al.: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182(5):598-604.
• [3]Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M: Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(1):6-14.
• [4]Stockley RA: Biomarkers in COPD: time for a deep breath. Thorax 2007, 62(8):657-660.
• [5]Sin DD, Vestbo J: Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6(6):543-545.
• [6]Jones PW, Agusti AG: Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006, 27(4):822-832.
• [7]Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B: Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007, 62(7):595-601.
• [8]Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, et al.: Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183(9):1187-1192.
• [9]Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(3):250-255.
• [10]de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Cordoba-Lanus E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR: C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133(6):1336-1343.
• [11]Mannino DM, Valvi D, Mullerova H, Tal-Singer R: Fibrinogen. COPD: COPD and Mortality in a Nationally Representative U.S. Cohort,  ; 2012.
• [12]Agusti A, Edwards LD, Rennard SI, Macnee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, et al.: Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS One 2012, 7(5):e37483.
• [13]Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M: Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184(6):637-641.
• [14]Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, et al.: Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177(3):269-278.
• [15]Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Muller C, Bingisser R, Struck J, Muller B, Tamm M: Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008, 134(2):263-272.
• [16]Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE: Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011, 139(6):1410-1418.
• [17]Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al.: Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184(6):662-671.
• [18]Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R: Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34(1):95-102.
• [19]Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R: Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008, 63(12):1058-1063.
• [20]Vestbo J, Rennard S: Chronic obstructive pulmonary disease biomarker(s) for disease activity needed–urgently. Am J Respir Crit Care Med 2010, 182(7):863-864.
• [21]Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diiagnosis, managment and prevention of COPD.  ,  ; 2010. Available from http://www.goldcopd.com/ webcite (last accessed August 2011)
• [22]Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
• [23]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [24]Rodriguez-Roisin R: Toward a consensus definition for COPD exacerbations. Chest 2000, 117(5 Suppl 2):398S-401S.
• [25]Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54(7):581-586.
• [26]Jones PW, Quirk FH, Baveystock CM: The St George's Respiratory Questionnaire. Respir Med 1991, 85(Suppl B):25-31. discussion 33–27
• [27] : ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
• [28]Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(23):2445-2454.
• [29]Make B: How can we assess outcomes of clinical trials: the MCID approach. COPD 2007, 4(3):191-194.
• [30]Nishimura K, Izumi T, Tsukino M, Oga T: Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121(5):1434-1440.
• [31]Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171(6):591-597.
• [32]Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, Kondragunta V, Lee JS, Zhang Y, Choi AM, et al.: The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009, 4(8):e6865.
• [33]Little FF, Lynch E, Fine G, Center DM, Cruikshank WW: Tumor necrosis factor-alpha-induced synthesis of interleukin-16 in airway epithelial cells: priming for serotonin stimulation. Am J Respir Cell Mol Biol 2003, 28(3):354-362.
• [34]Mineo D, Ambrogi V, Cufari ME, Gambardella S, Pignotti L, Pompeo E, Mineo TC: Variations of inflammatory mediators and alpha1-antitrypsin levels after lung volume reduction surgery for emphysema. Am J Respir Crit Care Med 2010, 181(8):806-814.
• [35]Tuder RM, Yoshida T, Arap W, Pasqualini R, Petrache I: State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc 2006, 3(6):503-510.
• [36]Valipour A, Schreder M, Wolzt M, Saliba S, Kapiotis S, Eickhoff P, Burghuber OC: Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008, 115(7):225-232.
• [37]Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y: Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009, 103(8):1231-1238.
• [38]Olafsdottir IS, Janson C, Lind L, Hulthe J, Gunnbjornsdottir M, Sundstrom J: Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study. Respirology 2010, 15(3):530-535.
• [39]Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, Shale DJ: Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6(2):81-87.
• [40]Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005, 25(5):885-890.
• [41]Davey A, McAuley DF, O'Kane CM: Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J 2011, 38(4):959-970.
• [42]Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(8):867-874.
• [43]Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R: COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12(1):146. BioMed Central Full Text
• [44]Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al.: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365(13):1184-1192.